CN104069078A - 阿托伐他汀钙药物组合物及其制备方法 - Google Patents
阿托伐他汀钙药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN104069078A CN104069078A CN201410223650.2A CN201410223650A CN104069078A CN 104069078 A CN104069078 A CN 104069078A CN 201410223650 A CN201410223650 A CN 201410223650A CN 104069078 A CN104069078 A CN 104069078A
- Authority
- CN
- China
- Prior art keywords
- atorvastatin calcium
- composition
- pregelatinized starch
- agent
- calcium carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001770 atorvastatin calcium Drugs 0.000 title claims abstract description 45
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title abstract description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 46
- 239000007919 dispersible tablet Substances 0.000 claims abstract description 39
- 229920000881 Modified starch Polymers 0.000 claims abstract description 23
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 23
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 238000004090 dissolution Methods 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 230000029087 digestion Effects 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 17
- 239000012535 impurity Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 230000007774 longterm Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
实施例 | 外观 | 分散均匀性 | 硬度 | 片重差异 |
1 | 光洁 | 1分10秒 | 合格 | 合格 |
2 | 光洁 | 1分18秒 | 合格 | 合格 |
3 | 光洁 | 1分13秒 | 合格 | 合格 |
0月 | 12月 | 24月 | 36月 | |
本发明实施例1 | 0.09 | 0.11 | 0.24 | 0.30 |
本发明实施例2 | 0.13 | 0.16 | 0.29 | 0.37 |
本发明实施例3 | 0.11 | 0.16 | 0.27 | 0.38 |
对比实施例1 | 0.24 | 0.38 | 0.52 | 0.68 |
对比实施例2 | 0.14 | 0.31 | 0.47 | 0.65 |
对比实施例3 | 0.18 | 0.34 | 0.46 | 0.67 |
0月 | 12月 | 24月 | 36月 |
本发明实施例1 | 0.52 | 0.57 | 0.74 | 0.89 |
本发明实施例2 | 0.56 | 0.60 | 0.82 | 0.99 |
本发明实施例3 | 0.55 | 0.61 | 0.79 | 0.96 |
对比实施例1 | 0.78 | 0.98 | 1.22 | 1.54 |
对比实施例2 | 0.62 | 0.95 | 1.16 | 1.58 |
对比实施例3 | 0.65 | 0.96 | 1.15 | 1.47 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410223650.2A CN104069078B (zh) | 2014-05-22 | 2014-05-22 | 阿托伐他汀钙药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410223650.2A CN104069078B (zh) | 2014-05-22 | 2014-05-22 | 阿托伐他汀钙药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104069078A true CN104069078A (zh) | 2014-10-01 |
CN104069078B CN104069078B (zh) | 2019-06-11 |
Family
ID=51590949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410223650.2A Active CN104069078B (zh) | 2014-05-22 | 2014-05-22 | 阿托伐他汀钙药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104069078B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107744507A (zh) * | 2017-09-29 | 2018-03-02 | 西藏九瑞健康股份有限公司 | 一种阿托伐他汀钙药物组合物及其制备方法 |
CN107982223A (zh) * | 2017-11-27 | 2018-05-04 | 诺唯德(天津)制药有限公司 | 一种阿托伐他汀钙片剂及其制备方法 |
CN108421045A (zh) * | 2018-04-02 | 2018-08-21 | 北京海晶生物医药科技有限公司 | 一种阿托伐他汀钙组合物、制剂及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686104A (en) * | 1993-01-19 | 1997-11-11 | Warner-Lambert Company | Stable oral CI-981 formulation and process of preparing same |
CN1805741A (zh) * | 2003-06-12 | 2006-07-19 | 沃纳-兰伯特公司 | 利用湿法造粒制备的稳定的阿托伐他汀组合物 |
CN1911209A (zh) * | 2006-08-25 | 2007-02-14 | 石家庄欧意药业有限公司 | 可快速崩解的阿托伐他汀钙片剂及其制备方法 |
CN101612403A (zh) * | 2009-08-13 | 2009-12-30 | 王丽燕 | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 |
CN102920675A (zh) * | 2012-11-29 | 2013-02-13 | 河南润弘制药股份有限公司 | 一种阿托伐他汀钙片及其制备方法 |
CN103705484A (zh) * | 2014-01-03 | 2014-04-09 | 华北制药集团新药研究开发有限责任公司 | 一种稳定的阿托伐他汀钙片及其制备方法 |
-
2014
- 2014-05-22 CN CN201410223650.2A patent/CN104069078B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5686104A (en) * | 1993-01-19 | 1997-11-11 | Warner-Lambert Company | Stable oral CI-981 formulation and process of preparing same |
CN1805741A (zh) * | 2003-06-12 | 2006-07-19 | 沃纳-兰伯特公司 | 利用湿法造粒制备的稳定的阿托伐他汀组合物 |
CN1911209A (zh) * | 2006-08-25 | 2007-02-14 | 石家庄欧意药业有限公司 | 可快速崩解的阿托伐他汀钙片剂及其制备方法 |
CN101612403A (zh) * | 2009-08-13 | 2009-12-30 | 王丽燕 | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 |
CN102920675A (zh) * | 2012-11-29 | 2013-02-13 | 河南润弘制药股份有限公司 | 一种阿托伐他汀钙片及其制备方法 |
CN103705484A (zh) * | 2014-01-03 | 2014-04-09 | 华北制药集团新药研究开发有限责任公司 | 一种稳定的阿托伐他汀钙片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
崔跃等: "预胶化淀粉在固体制剂中的应用", 《中国医药指南》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107744507A (zh) * | 2017-09-29 | 2018-03-02 | 西藏九瑞健康股份有限公司 | 一种阿托伐他汀钙药物组合物及其制备方法 |
CN107982223A (zh) * | 2017-11-27 | 2018-05-04 | 诺唯德(天津)制药有限公司 | 一种阿托伐他汀钙片剂及其制备方法 |
CN108421045A (zh) * | 2018-04-02 | 2018-08-21 | 北京海晶生物医药科技有限公司 | 一种阿托伐他汀钙组合物、制剂及其制备方法 |
CN108421045B (zh) * | 2018-04-02 | 2021-09-24 | 北京海晶生物医药科技有限公司 | 一种阿托伐他汀钙组合物、制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104069078B (zh) | 2019-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170340569A1 (en) | Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases | |
CN102920675B (zh) | 一种阿托伐他汀钙片及其制备方法 | |
CN104306348B (zh) | 一种辛伐他汀片及其制备方法 | |
CN103877079A (zh) | 阿托伐他汀钙药物组合物 | |
CN103705484B (zh) | 一种稳定的阿托伐他汀钙片及其制备方法 | |
WO2019149917A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
CN104069078A (zh) | 阿托伐他汀钙药物组合物及其制备方法 | |
CN101204389A (zh) | 一种含有重酒石酸卡巴拉汀的药物组合物及其制备方法 | |
CN101972260B (zh) | 一种瑞舒伐他汀钙口服药物组合物 | |
CN108245516B (zh) | 一种含瑞舒伐他汀钙的药物组合物及其制备方法 | |
CN105343024A (zh) | 一种阿托伐他汀钙片剂及其制备方法 | |
CN104940204A (zh) | 一种替格瑞洛固体制剂及其制备方法 | |
WO2021196982A1 (zh) | 一种抗心律失常的药物组合物及制备方法 | |
CN103505425A (zh) | 一种稳定的匹伐他汀钙片 | |
CN108721238A (zh) | 一种碳酸锂缓释片 | |
CN102697749A (zh) | 盐酸贝那普利片的制备方法 | |
CN103127016B (zh) | 富马酸比索洛尔片剂组合物及其制备方法 | |
CN107744507B (zh) | 一种阿托伐他汀钙药物组合物及其制备方法 | |
CN103784417A (zh) | 一种含硅酸镁的匹伐他汀钙片及其制备方法 | |
US10376470B2 (en) | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | |
CN109044989A (zh) | 一种阿托伐他汀钙胶囊制剂及其制备方法 | |
CN106038523B (zh) | 一种枸橼酸钾枸橼酸钠片及其制备方法 | |
CN107550875A (zh) | 一种稳定的非诺贝酸片及其制备方法 | |
CN102600131A (zh) | 一种含有依折麦布和辛伐他汀的药物组合物及制备方法 | |
CN109432032A (zh) | 一种瑞舒伐他汀钙片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170105 Address after: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Applicant after: XIZANG JIURUI HEALTH Co.,Ltd. Address before: Room 12, building 93, Wanda Plaza, No. 100022 Jianguo Road, Beijing, Chaoyang District, China Applicant before: An Dong |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: XIZANG JIURUI HEALTH Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: XIZANG JIURUI HEALTH Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
CP03 | Change of name, title or address |
Address after: No.13, block B, Yangguang new town, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, 851400 Patentee after: JIURUI health Co.,Ltd. Address before: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee before: XIZANG JIURUI HEALTH Co.,Ltd. |
|
CP03 | Change of name, title or address |